BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prandin / NovoNorm (repaglinide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Prandin / NovoNorm (repaglinide)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07881224-285@assetmemo.bio
DTSTAMP:20261121T004514Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Prandin / NovoNorm (repaglinide): Phase 1 readout est. (NCT07881224
 )
DESCRIPTION:Prandin / NovoNorm (repaglinide)\, phase 1.\nStudy: A Multiple-
 dose Study Investigating the Drug-drug Interaction Potential and QTc Effec
 ts of Fosmanogepix in Healthy Adult Subjects\nEstimated primary completion
 : 9 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repag
 linide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07881224
URL:https://assetmemo.bio/drug/repaglinide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912268-285@assetmemo.bio
DTSTAMP:20261121T004514Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Prandin / NovoNorm (repaglinide): Phase 1 readout est. (NCT07912268
 )
DESCRIPTION:Prandin / NovoNorm (repaglinide)\, phase 1.\nStudy: Study of SI
 M0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced 
 or Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 1 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repagl
 inide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07912268
URL:https://assetmemo.bio/drug/repaglinide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
